



# ICPerMed Virtual Conference Personalised Medicine – From Vision to Practice

February 25-26, 2021

## PROGRAMME OVERVIEW

### Objectives

During the conference, ICPerMed will be committed to demonstrate the importance and the need to address personalised medicine challenges about **patient preferences, data harmonisation, personalised medicine implementation into healthcare systems, collaboration between academia and industry and, finally, on health economics aspects.**

A session on “The challenges to a Personalised Medicine Approach for infectious diseases – Lessons learned from the COVID-19 pandemic” will be dedicated to the **COVID-19 pandemic and how personalised medicine approaches could be part of the solutions.**

Furthermore, ICPerMed will feature and honour during the event best practices in personalised medicine research through the **ICPerMed Recognition 2020**, aiming to recognise, encourage, promote and disseminate outstanding examples.



**DAY 1**

*February 25<sup>th</sup> 13:00 – 19:00 CET*

**Welcome & Opening Statements**

- 13:00 – 14:20 **Thierry Damerval**, CEO of ANR  
**Irene Norstedt**, Director for the People Directorate - Directorate "Research and Innovation" (RTD), European Commission  
**Ejner Moltzen**, Innovation Fund Denmark, Chair of ICPerMed  
**Eduardo Cazap**, Latin American & Caribbean Society of Medical Oncology SLACOM, Scientific Committee

**Session: Informed and engaged citizens - personalised medicine for the individual and society**

*Chairs: Dr. Mette Hartlev & David Haerry*

Through this session, it will be discussed how and when to include patient perspectives in the development life cycle of personalised medicals, prevention, products and interventions. The session will show the opportunities, benefits and barriers of patient empowerment in healthcare, research activities or policy development. The session will show the importance of the patient's role to provide an overarching perspective and first-hand experience on what it is like to live with a disease, and by doing that, ensuring that interventions truly respond to patient needs and priorities. Conversely, due to the complexity of personalised medicine, it is challenging to engage patients and citizens. A focus will be made on the data integration and management as well as on education and training that are required to allow patients and patient organisations to contribute to research and to disseminate health-related information through their communities.

- 14:20 – 14:25 **Introduction by Dr. Mette Hartlev & David Haerry**  
14:25 – 14:45 **Bettina Ryll**  
***Personalised Medicine – When you are the patient, what is personal enough?***  
Horizon Europe Cancer Mission Board and Melanoma Patient Network Europe, Sweden
- 14:45 – 15:05 **Barbara Prainsack**  
***The role of patient participation in Personalised Medicine***  
Department of Political Science, University of Vienna, Austria
- 15:05 – 15:45 **Panel Discussion:**  
**Bettina Ryll**  
**Barbara Prainsack**  
**Peter Goodhand**, GA4GH, Canada



**Larry Norton**, Memorial Sloan Kettering Cancer Center, USA

15:45 – 15:55 **Break (10 min)**

**Session: Enhancing life science- and health-related data through biomedical research, data harmonisation and regulatory frameworks**

*Chair: Dr. Alfonso Valencia*

Data and data analytics are basic pillars of personalised medicine. Handling and interoperating large heterogeneous data sets represent a conceptual and technical challenge, including issues of data protection and security, infrastructure and computational resources, as well as the need of making data and data interpretation accessible to a diversity of end-users from patients and scientist to medical doctors. Data infrastructure and technical solutions will be presented on how to allow access to biomedical and medical data and how to achieve the integration of data sources of disparate nature.

15:55 – 16:00 **Introduction by Dr. Alfonso Valencia**

16:00 – 16:20 **Peter Goodhand**

***The Changing World of Human Genomic Data Sharing***

CEO Global Alliance for Genomics and Health (GA4GH), Canada

16:20 – 16:40 **Søren Brunak**

***Longitudinal Phenotypes and Disease Trajectories at Population Scale***

Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen, Denmark

16:40 – 17:20 Panel Discussion:

**Peter Goodhand**

**Søren Brunak**

**Barbara Prainsack**, University of Vienna, Austria

**Ernst Hafen**, ETH Zurich, Switzerland

17:20 – 17:30 **Break (10 min)**

**Session: Enabling healthcare systems to implement the next generation of medicine: a crucial shift**

*Chair: Prof. Eduardo Cazap*

The implementation of personalised medicine is a paradigm shift for our current healthcare systems and will require a switch from a system focusing on treating diseases to a system ensuring that appropriate preventive measures are set in place, that early diagnosis is made



or optimal therapies are selected. This session will provide an insight from a public health expert view on the design, implementation and evaluation of healthcare system reforms and on how to facilitate and guarantee an equitable access to personalised healthcare for all citizens. The session will furthermore demonstrate how genomics and technologies are changing the practice of medicine and public health improving health population and disease prevention.

- 17:30 – 17:35 **Introduction by Prof. Eduardo Cazap**  
17:35 – 17:55 **Rifat Atun**  
*Health Systems, Innovation and Precision Medicine*  
Harvard University, USA
- 17:55 – 18:15 **Andres Metspalu**  
*From biobanking to personal medicine and disease prevention*  
Estonian Genome Project, Estonia
- 18:15 – 18:55 Panel Discussion:  
**Rifat Atun**  
**Andres Metspalu**  
**Rizwana Mia, SAMRC, South Africa**

## DAY 2

February 26<sup>th</sup> 13:00 – 19:00 CET

13:00 – 13:10 **Opening by ANR, ICPerMed Secretariat**

### Session: ICPerMed Recognition

*Chair: Dr. Gaetano Guglielmi, ICPerMed Secretariat, Italian Ministry of Health, Italy*

ICPerMed features and honours in this session best practices in personalised medicine research through the ICPerMed Recognition 2020, that aims to recognise, encourage, promote and disseminate outstanding examples. The third ICPerMed Recognition edition was open to candidates worldwide, who have published scientific papers or developed best practice strategies in the field of personalised medicine between 1st January 2018 and 31st October 2019. The winners will present their results during this session.

13:10 – 14:10 **Introduction by Dr. Gaetano Guglielmi**

**Maritha Kotze**



***A pathology-supported genetic testing platform for application of breast cancer pharmacogenetics at the point of care (POC) using an integrated service and research approach***

Department of Pathology, Stellenbosch University and National Health Laboratory Service - NHLS- Tygerberg Hospital, South Africa

**Daniela Gallo**

***A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer***

Sacro Cuore Cattolica University, Italy

**Daryl Pritchard**

***The Personalised Medicine Coalition: Developing Strategies for the Integration of Personalised Medicine in Health Care Practice***

Science Policy at PMC, USA

**Winfried Schlee**

***International Tinnitus Research – Novel approaches in Personalised Medicine Research, Teaching and Treatment - The ESIT Project***

The ESIT Consortium

14:10 – 14:20 **Break (10 min)**

**Session: Building an efficient entrepreneurial ecosystem supporting health innovation**

*Chairs: Dr. André Albergaria & Dr. Salah Dine Chibout*

This session will focus on the importance to bridge the gap between research and innovation based on a better cooperation between academia and industry. Solutions will be presented on how the transfer of clinical and biomedical research to routine healthcare can be facilitated and organised through an ecosystem supporting partnerships and collaborations. Additionally, the session will show how medical education will improve collaboration and research through mutual understanding and allow a better and more complete flow of information in translating biomedical discoveries into clinical practices.

14:20 – 14:25 **Introduction by Dr. André Albergaria & Dr. Salah Dine Chibout**

14:25 – 14:45 **Vjera Magdalenic-Moussavi**

***Building bridges - how industry academia collaborations can breeze the gap of innovation***



- 14:45 – 15:05 Director of Industry Partnerships and Commercialisation, Medicine at Imperial College London, UK  
**Magda Chlebus**  
Executive Director for Science Policy and Regulatory Affairs of The European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
- 15:05 – 15:45 Panel Discussion:  
**Vjera Magdalenic-Moussavi**  
**Magda Chlebus**  
**Fabrice André**, Gustave Roussy, France  
**Aurélie Grienenberger**, Eligo Bioscience, France
- 15:45 – 15:55 **Break (10 min)**

**Session: Personalised medicine, an opportunity to redefine value in healthcare by incorporating patient preference and socio-economics aspects**

*Chair: David Haerry*

Healthcare systems face rising costs due to technological developments, increasing number of patients with chronic diseases and expensive personalised medicine treatments. Additionally, healthcare systems should be based on solidarity and guarantee an equitable access to care. The session will show novel approaches to value assessment beyond conventional cost-effectiveness analysis and centred on patient preferences. As the notion of value still differs between citizens, patients, healthcare providers, health professional, industry but also healthcare systems, it is necessary to define a comprehensive meaning of value. The session will welcome health economists and national authorities to provide insight on how personalised medicine will be valued in future healthcare systems on emerging issues as access, costs, prices and reimbursement.

- 15:55 – 16:00 **Introduction by David Haerry**
- 16:00 – 16:20 **Axel Mühlbacher**  
***Patient Involvement in Healthcare Decision Making: Is there a rationale for considering patient preferences?***  
Institute for Health Economics and Health Care Management, Hochschule Neubrandenburg, Germany & Duke University, USA
- 16:20 – 16:40 **Wiebke Löbker**  
Head of Unit Innovation, Change management / Personal advisor to the president of the BfArM Federal Institute for Drugs and Medical Devices, Germany,
- 16:40 – 17:20 Panel Discussion:



**Axel Mühlbacher**  
**Wiebke Löbker**  
**Serena Scollen, ELIXIR**  
**Break (10 min)**

17:20 – 17:30

**Session: The Challenges to a Personalised Medicine Approach for infectious diseases –  
Lessons learned from the COVID-19 pandemic**

*Chair: Prof. Eric Solary*

This session will highlight the opportunities offered by personalised medicine to fight infectious diseases through lessons learned from the COVID-19 pandemic. We will discuss the latest scientific advances in diagnostics about the severity and susceptibility of COVID-19 infections and their association with certain gene variations found in the population. Research in -omics is therefore essential to the understanding of this pathology. A major challenge in the management of the disease will be to evaluate the kinetics of the disease and the risk of progression to more severe forms. Taking together, this knowledge would allow to decipher biological pathways involved in disease susceptibility and progression in order to test and develop or reposition drugs specifically targeting those biological pathways or clinical forms that could work, not only in patients with specific genetics changes, but also for the entire population. In this way, the management of COVID-19 patients ideally goes beyond a simple “one disease, one treatment” but towards “a disease with a clinic-biological form, a particular kinetics and therefore a particular treatment”.

We will discuss about the importance of multidisciplinary approaches and the necessity of the implementation of “bed to the bench” research as already supported by personalised medicine approaches, particularly in the rare disease and cancer field. We will show how intersectoral synergies and coordinated databases stimulate research and could help developing knowledge on the disease and translation to the clinics. The relevance of biological and genetic data collection as well as follow-up capabilities will be outlined.

17:30 – 18:30

**Moderation by Eric Solary**

**Jacques Fellay**, École Polytechnique Fédérale de Lausanne (EPFL),  
Switzerland

**Alberto Mantovani**, Istituto Clinico Humanitas

**Oliver Cornely**, University Hospital Cologne, Germany

**Guy Cochrane**, EMBL-EBI, European Open Science Cloud, European  
COVID-19 Data platform

18:30 – 18:45

**Summary and Closing Remarks**



## Scientific Committee



**André Albergaria**

Institute of Molecular Pathology and Immunology IPATIMUP



**Eduardo Cazap**

Latin American & Caribbean Society of Medical Oncology SLACOM



**Salah-Dine Chibout**

Novartis Institutes for BioMedical Research



**David Haerry**

European Patients' Academy on Therapeutic Innovation EUPATI



**Mette Hartlev**

University of Copenhagen



**Alfonso Valencia**

Barcelona Supercomputing Centre



## Virtual Platform

The ICPerMed Conference 2021 'Personalised Medicine – From Vision to Practice' will take place on an online platform. Participants will have access to all information and features related to the ICPerMed conference from a single intuitive dashboard, including a poster space, their personal participant profile and notably the virtual stage (virtual conference room) to assist the sessions.

Within the virtual stage, participants will have the opportunity to comment and ask questions through a public chat visible by everyone.

Participants can also connect outside the conference room through private chats.

For an insight, please consult this [short video](#) on How to Start a Chat (0:31).

Attendees will also have access to a networking module offering the possibility to ask and schedule private visioconference meetings.

For a quick overview, please consult this [short video](#) (0:22).

For more details on the networking module and how it works, please consult [this tutorial](#) (2:10)

While it is not mandatory, we recommend to the participants to complete their profile either during the registration process or after, by log in to the platform. The participant profile will serve to find relevant attendees with whom to connect.

*Opening of the virtual platform:*

*February 1<sup>st</sup>, 2021*